Intravenous infusion of ferric carboxymaltose can cause a transient hypophosphatemia.
Clinical findings:
(1) recent intravenous infusion of ferric carboxymaltose
(2) serum phosphorus < 2.0 mg/dL with nadir about 2 weeks after the infusion
(3) return to normal phosphorus concentrations in 4-6 weeks
Often the patient is asymptomatic but symptoms can develop after high or repeated doses.
Findings in severe cases may include:
(1) fatigue
(2) muscle cramps
(3) osteomalacia
